S
Shenzhen Beimei Pharmaceutical
Specialized pharmaceutical developer of pediatric prescription medicines
About Shenzhen Beimei Pharmaceutical
Shenzhen Beimei Pharmaceutical Co., Ltd. is a pharmaceutical company founded in 2010 by Claire Wu that specializes in pediatric prescription medicines. Wu, who serves as CEO and General Manager, has over 20 years of experience in pharmaceutical marketing, sales, and R&D. The company aims to address the challenges of pediatric medication by developing high-quality, accurately-dosed, and palatable products for children.
Beimei Pharmaceutical operates with a dual strategy of in-house research and development combined with global collaboration through in-licensing and asset acquisitions. This approach allows the company to integrate R&D, manufacturing, and commercialization. The company's product pipeline includes over 40 pediatric drugs, with 7 already on the market, covering therapeutic areas such as dermatology, respiratory, gastroenterology, anti-infection, neurology, neonatal, and endocrinology. A key product is TWYNEO®, an FDA-approved cream for acne vulgaris, for which Beimei acquired the commercial rights in China and Israel in May 2024. Beimei has established a nearly 3,000-square-meter R&D center and has built proprietary technology platforms for pediatric sustained-release formulations, oral thin films, and topical transdermal gels.
The company's business model is centered on the development and commercialization of these specialized pediatric drugs. Revenue is generated through the sale of its approved products. Beimei Pharmaceutical has formed strategic long-term partnerships with major international pharmaceutical firms, including Hetero, Cipla, Dr. Reddy's, and Sol-Gel. The company is venture capital-backed, having completed multiple funding rounds, including Angel, Series A, B/B+, and C, with backing from institutions like Efung Capital and Nanshan Zhanxin Investment.
Source: Dealroom company dataNews
Open roles
Shenzhen Beimei Pharmaceutical in the Shenzhen ecosystem
The Shenzhen Beimei Pharmaceutical office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
- ECEfung Capital
Series B and later3 investors entered at this stage
- NENanshan Strategic Emerging
Jiangsu Aosaikang Pharmaceutical- JFJiangsu Golden Bridge Private Equity Fund
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Shenzhen Beimei Pharmaceutical on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Shenzhen Beimei Pharmaceutical on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.


